What the study measured
Researchers started with 155,172 adults with type 2 diabetes in U.S. IQVIA health-plan claims from January 2016 through June 2025. They matched 17,412 adults with a recorded diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) to 17,412 adults without a recorded diagnosis and compared all-cause direct health care costs over 12 months [1].
The adjusted cost ratio was 1.62 (95% confidence interval 1.58–1.67). The statistical model estimated $11,411 more per person over 12 months (95% CI $10,725–$12,097). Hospital stays accounted for the largest estimated difference, $4,473 per person. The totals include what health plans and patients paid for hospital care, outpatient care, emergency visits and outpatient prescriptions, expressed in 2025 U.S. dollars [1].
How to interpret the spending difference
A comparison group without a recorded diagnosis may include people with undiagnosed MASLD. Guidance on fatty liver screening in type 2 diabetes addresses how clinicians assess the risk of fibrosis. The study records could not distinguish spending by fibrosis stage. Differences in underlying health and health care use can remain after matching, so the study cannot establish how much of the spending gap the disease caused [1].
Estimates of semaglutide’s cost-effectiveness for MASH address a separate question by modeling treatment costs and projected health benefits. The FDA’s accelerated approval for Wegovy injection covers adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with stages F2 to F3 [2]. The claims study included a broader diagnosed MASLD population.
For a prescription, GLP-1 coverage rules depend on the plan, the product and the condition being treated. The study’s combined spending figure cannot tell you what your insurer would cover or how much you would pay at the pharmacy.